Lead Product(s) : PGX-YBG
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : McMaster University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data demonstrated that PGX-processed yeast beta glucan (PGX-YBG) is respirable and able to safely and reliably reprogram macrophages in the lungs in pre-clinical mouse models.
Product Name : PGX-YBG
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : PGX-YBG
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : McMaster University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NEO6860
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : AazeinTX
Deal Size : Undisclosed
Deal Type : Agreement
Details : AazeinTx has acquired all rights to NEO6860, a clinical-stage TRPV1 antagonist in adMare’s technology portfolio. With a team at the University of Calgary led by Dr. Richard Wilson AazeinTx proposes to bring a pill-based form of NEO6860.
Product Name : NEO6860
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 17, 2021
Lead Product(s) : NEO6860
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : AazeinTX
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Brimonidine Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results of new investigational in vitro data shows that two benzalkonium chloride preserved eye drops, LUMIFY® redness reliever eye drops and BESIVANCE® 0.6%, indicated complete inactivation of Severe Acute Respiratory Syndrome-related Coronavirus 2 (S...
Product Name : Lumify
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : Brimonidine Tartrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vasculotide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : US Department of Defense
Deal Size : $2.8 million
Deal Type : Funding
Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001
Details : Funding will support the development AV-001 for the treatment of COVID-19-associated acute lung injury and acute respiratory distress syndrome (ARDS).
Product Name : AV-001
Product Type : Peptide
Upfront Cash : Undisclosed
August 18, 2020
Lead Product(s) : Vasculotide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : US Department of Defense
Deal Size : $2.8 million
Deal Type : Funding
Lead Product(s) : OB-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : National Research Council Industrial Research Assistance Program
Deal Size : Undisclosed
Deal Type : Funding
Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19
Details : Funding from the National Research Council Industrial Research Assistance Program will support the development of Orion’s lead compound, OB-002, a promising treatment for SARS-CoV-2 infection associated acute respiratory distress syndrome (ARDS).
Product Name : OB-002
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 30, 2020
Lead Product(s) : OB-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : National Research Council Industrial Research Assistance Program
Deal Size : Undisclosed
Deal Type : Funding